



Press release | Lund 2026-03-26

Coegin Pharma's management acquires shares in the company

Coegin Pharma AB today announces that the company's CEO, CFO and CMO have acquired additional shares in the company.

CEO Jens Eriksson has acquired 24,293 shares, CFO Lars Bukhave Rasmussen has acquired 26,300 shares, and CMO John Zibert has acquired 36,884 shares. In total, 87,477 shares have been acquired. Jens Eriksson's acquisition was made within the framework of the remuneration program approved by the Annual General Meeting in 2025.

Following the transactions, Jens Eriksson holds 503,497 shares in Coegin Pharma AB, Lars Bukhave Rasmussen holds 95,295 shares, and John Zibert holds 96,295 shares.

The acquisitions were carried out on Nordic SME.

For further information, please contact:

Jens Eriksson, CEO, Coegin Pharma AB

Email: je@coeginpharma.com

About Coegin Pharma

Coegin Pharma is a Swedish biotech company with cutting-edge innovations for hair and skin. The company is currently commercializing its patented hair growth innovation Follicopeptide® on a global scale. In development is NPP-4, a next-generation peptide that represents a novel approach to regulating skin pigmentation through advanced biotechnology.

Coegin Pharma's share is listed on NGM Nordic SME and dual-listed on Börse Stuttgart. The company is headquartered in Lund, Sweden.

More information – including subscription to company updates and links to social media – is available at coeginpharma.com

Coegin Pharma AB

c/o Medicon Village

223 81 Lund, Sweden

Registration number

559078-0465

coeginpharma.com

info@coeginpharma.com

